EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long-term Pegvisomant Therapy of Acromegaly: Effects on Bone Density, Turnover and Microstructure Using HRpQCT

Adriana P Kuker, Sanchita Agarwal iD, Elizabeth Shane, Juliana Bicca, Eliza B Geer, Serge Cremers, Elzbieta Dworakowski, Adi Cohen, Thomas L Nickolas, Emily M Stein, Pamela U Freda iD

Journal of the Endocrine Society · 06.04.2024 · 8 (6)

DOI: 10.1210/jendso/bvae079 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the Endocrine Society, online erschienen am 17.04.2024. Verfasst von Adriana P Kuker und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NCRR NIH HHS, NIAMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Fracture rate is increased in patients with active acromegaly and those in remission. Abnormalities of bone microstructure are present in patients with active disease and persist despite biochemical control after surgery. Effects of treatment with the GH receptor antagonist pegvisomant on bone microstructure were unknown.

Methods

We studied 25 patients with acromegaly (15 men, 10 women). In 20, we evaluated areal bone mineral density (BMD) by dual-energy X-ray absorptiometry and bone turnover markers (BTMs) longitudinally, before and during pegvisomant treatment. After long-term pegvisomant in 17, we cross-sectionally assessed volumetric BMD, microarchitecture, stiffness, and failure load of the distal radius and tibia using high-resolution peripheral quantitative computed tomography (HRpQCT) and compared these results to those of healthy controls and 2 comparison groups of nonpegvisomant-treated acromegaly patients, remission, and active disease, matched for other therapies and characteristics.

Results

In the longitudinal study, areal BMD improved at the lumbar spine but decreased at the hip in men after a median ∼7 years of pegvisomant. In the cross-sectional study, patients on a median ∼9 years of pegvisomant had significantly larger bones, lower trabecular and cortical volumetric density, and disrupted trabecular microarchitecture compared to healthy controls. Microstructure was similar in the pegvisomant and acromegaly comparison groups. BTMs were lowered, then stable over time.

Conclusion

In this, the first study to examine bone microstructure in pegvisomant-treated acromegaly, we found deficits in volumetric BMD and microarchitecture of the peripheral skeleton. BTM levels remained stable with long-term therapy. Deficits in bone quality identified by HRpQCT may play a role in the pathogenesis of fragility in treated acromegaly.

Schlagwörter

Stichwörter der Autor:innen

HRpQCTacromegalybone

Autor:innen und Institutionen

  • Department of Medicine, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA.
  • Plenicca Clinic, Sao Paolo 05688-021, Brazil.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
  • Department of Pathology and Cell Biology, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA.
  • Endocrinology and Metabolic Bone Diseases, Hospital for Special Surgery, New York, NY 10021, USA.

ORCID-Profile: Sanchita Agarwal, Pamela U Freda

Förderung

  • NIDDK NIH HHS
  • NCRR NIH HHS
  • NIAMS NIH HHS
  • NCI NIH HHS
  • National Institutes of Health
  • Pfizer
  • Columbia University
  • National Center for Research Resources

Zitieren

APA

Kuker, A. P., Agarwal, S., Shane, E., Bicca, J., Geer, E. B., Cremers, S., Dworakowski, E., Cohen, A., Nickolas, T. L., Stein, E. M., & Freda, P. U. (2024). Long-term Pegvisomant Therapy of Acromegaly: Effects on Bone Density, Turnover and Microstructure Using HRpQCT. Journal of the Endocrine Society, 8(6). https://doi.org/10.1210/jendso/bvae079

Vancouver

Kuker AP, Agarwal S, Shane E, Bicca J, Geer EB, Cremers S, et al. Long-term Pegvisomant Therapy of Acromegaly: Effects on Bone Density, Turnover and Microstructure Using HRpQCT. Journal of the Endocrine Society. 2024;8(6). doi:10.1210/jendso/bvae079

BibTeX
@article{Kuker2024,
  author = {Kuker, Adriana P and Agarwal, Sanchita and Shane, Elizabeth and Bicca, Juliana and Geer, Eliza B and Cremers, Serge and Dworakowski, Elzbieta and Cohen, Adi and Nickolas, Thomas L and Stein, Emily M and Freda, Pamela U},
  title = {Long-term Pegvisomant Therapy of Acromegaly: Effects on Bone Density, Turnover and Microstructure Using HRpQCT},
  journal = {Journal of the Endocrine Society},
  year = {2024},
  volume = {8},
  number = {6},
  doi = {10.1210/jendso/bvae079}
}
Kostenlos starten →